Direct antigonadal activity of cannabinoids: suppression of rat granulosa cell functions.
The direct effects of delta 9-tetrahydrocannabinol (THC) and related cannabinoids on ovarian granulosa cells were studied in vitro. Granulosa cells from immature, hypophysectomized, estrogen-treated rats were cultured for 2 days in an androstenedione-supplemented medium in the presence or absence of follicle-stimulating hormone (FSH) (10 ng/ml) with or without cannabinoids. FSH treatment increased progesterone and estrogen biosynthesis, whereas concomitant treatment with THC led to a dose-dependent inhibition of the FSH-stimulated accumulation of progesterone and estrogen with ED50 values of 3.5 +/- 0.3 X 10(-7) and 1.8 +/- 0.2 X 10(-6) M, respectively. Treatment with related but nonpsychoactive cannabinoids (cannabidiol, cannabinol, cannabigerol, or cannabichromene) was equally effective. The THC-induced inhibition of progesterone production was reversible and was associated with an inhibition of pregnenolone biosynthesis and a decrease of 3 beta-hydroxysteroid dehydrogenase activity. In addition, treatment with THC brought about a dose-dependent inhibition of the FSH-induced increase in luteinizing hormone (LH) receptors. The inhibitory effects of THC were not associated with changes in cell number, protein content, or cell viability. Thus, THC exerts direct inhibitory effects on FSH-dependent functions related to steroidogenesis and the acquisition of LH receptors, all of which are essential to follicular maturation. Because plasma concentrations of THC similar to those used in this study have been reported in human beings, repeated exposure of female users to THC may lead to ovarian dysfunction, due in part, to the direct antigonadal activity to THC.
D015096:3-Hydroxysteroid Dehydrogenases / Q000378:metabolism; D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology*; D006063:Chorionic Gonadotropin / Q000378:metabolism; D004054:Diethylstilbestrol / Q000494:pharmacology; D013759:Dronabinol / Q000494:pharmacology*; D004343:Drug Implants; D005260:Female; D006107:Granulosa Cells / Q000187:drug effects / Q000502:physiology*; D007016:Hypophysectomy; D007700:Kinetics; D007986:Luteinizing Hormone / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000378:metabolism; D011974:Receptors, LH; D013329:Structure-Activity Relationship
D002186:Cannabinoids; D006063:Chorionic Gonadotropin; D004343:Drug Implants; D011956:Receptors, Cell Surface; D011974:Receptors, LH; D004054:Diethylstilbestrol; D013759:Dronabinol; D007986:Luteinizing Hormone; D015096:3-Hydroxysteroid Dehydrogenases